Skip to main content

The FDA's new director has a differing take on new technology...

Dr. Scott Gottlieb, The new head of the FDA, has made his feelings about mobile health regulation very clear. In 2014, he co-authored a piece for the Wall Street Journal about the FDA’s approach to mobile health and in 2015 he wrote a piece for Forbes. In both, he argued that FDA regulation of mobile health stifles innovation for little benefit.
“The ambiguity created by the guidance and the agency’s premarket review processes forces innovators to seek the FDA’s nod for every new launch and every small advance,” Gottlieb and co-author Colleen Klasmeier wrote for the Journal. “This slows progress to a crawl. Worse, the lag may be almost entirely unnecessary, as most of these products are not properly regarded as a medical device in the first place.”
Gottlieb argues that regulation for mobile health should be the exception, not the rule.  This would allow innovators and small companies the ability to provide home users with many beneficial monitoring devices.
“Most of these products pose very low risk to consumers,” Gottlieb wrote in the Forbes piece. “They’re meant to help people track and interpret their own health information. In that respect, they often do little more than help consumers organize information that they could glean for themselves – albeit far less reliably – using the Internet. But since many of the more sophisticated offerings help people diagnose their own illness, FDA says they meet the definition of being a medical device. That makes them subject to a regulatory scheme that was crafted more than 40 years ago, before these technologies were ever imagined.”
Specifically, Gottlieb argues that the point at which a digital health device or app requires regulation is exactly the point at which it becomes innovative, and as a result large companies like Apple are “dumbing down” consumer products, excluding health features they technically could build to elude the FDA.
“FDA has said it doesn’t intend to regulate ‘general wellness’ apps and mobile tech, like fitness and calorie trackers,” Gottlieb wrote in 2015. “But if these platforms make disease-specific claims, FDA wants to review them. When does an app cross that line? Any time it does something smart. Envision a nutrition app that counts your calories and tracks how your diet might raise or lower your risk for diabetes, or cause blood sugar surges. Or an app that helps correlate your symptoms with a list of probable causes.”
As to a solution, Gottlieb has advocated passing responsibility for digital health tools away from the FDA entirely, either to a newly created government group or to the industry to self-regulate.  Gottlieb contends that it’s exactly what was done with EHRs at a time when they were a political priority and those in power at HHS didn’t want their adoption to be stymied by FDA regulation.
This will allow for greater future innovations and offerings of the Helo!  I'm not for all deregulation, but there are definite areas where it needs to occur, and this is one!  

Comments

Popular posts from this blog

Not all fitness trackers are equal...

When you are looking at a fitness band, we often buy the cheapest...  the one that barely performs what we wanted it to do, has no potential for expanding.  It's no wonder we become frustrated and stop using it.  Money wasted...   Sometimes, an investment in quality with the ability for upgrades is the better way to spend the money...  something that will meet your needs today, and in the future. Let me introduce you to HELO LX As you can see, the price point of Helo LX is comparable to the upper end fitness monitors.  But look at the features, especially the features being added! As you can see, Helo LX goes beyond a fitness tracker.  It is also the only one that is a business opportunity!  Just by buying a Helo LX, you become registered in the business...  all you have to do is share your personal website with anyone who asks about your bracelet....   Click here for more information!!

An abstract of an article showing reliability of PPG based blood pressure and blood glucose monitoring

Format :  Abstract Send to Artif Intell Med.  2011 Oct;53(2):127-38. doi: 10.1016/j.artmed.2011.05.001. Epub 2011 Jun 22. Non-invasive estimate of  blood glucose  and  blood  pressure from a photoplethysmograph by means of machine learning techniques. Monte-Moreno E 1 . Author information 1 Department Signal Theory and Communications, Universitat Politècnica de Catalunya, Campus Nord, Edifici D5, C/Jordi Girona, Barcelona, Spain. enric.monte@upc.edu Abstract OBJECTIVE: This work presents a system for a simultaneous non-invasive estimate of the  blood glucose  level (BGL) and the systolic (SBP) and diastolic (DBP)  blood  pressure, using a photoplethysmograph (PPG) and machine learning techniques. The method is independent of the person whose values are being measured and does not need calibration over time or subjects. METHODOLOGY: The architecture of the system consists of a photoplethysmograph sensor, an activity detection module, a signal

How I decided Helo Lx was not a scam...

Why Helo LX? That's what I asked myself after being introduced to the Helo LX bracelet... So here are my thoughts... My name is Bryan Kentner, DPM.  I'm a podiatrist, and as such I work with a large population of seniors.  My goal has always to keep my patients healthy, active and to allow them to remain independent for as long as possible. Many of my seniors live on their own, which sometimes cause an issue with their children.  In my practice, I would recommend Life alert type products to help alleviate some of these concerns.  The product required a 3 year contract, and had a $50 monthly fee...  and lacked some features I wanted... Along comes Helo LX...  At first glance, I wrote it off as a MLM scam fitbit with an SOS feature, marketing monitoring features that couldn't be real.  I researched the device, and what the sensors could, and could not do, expecting satisfaction that my first impression was indeed correct. However, I found it used the same sens